Scotiabank Stands Firm on Merck & Co Amid Strong Immuno-Oncology Growth

Scotiabank has maintained its Sector Outperform rating on Merck & Co's stock, setting a price target of $180.00. This implies an upside of 21.1% from the September 28 close of $148.69.

The bank cites Merck's strong leadership in immuno-oncology, particularly with Keytruda, which continues to drive substantial revenue growth and investor confidence in the company's long-term sales trajectory.

Additionally, Scotiabank notes that Merck has a diverse revenue stream, including a robust vaccine business and a significant presence in animal health. This positions the company well to mitigate risks associated with patent expirations and competitive pressures in its pharmaceutical segment.